CARDIFF, United Kingdom, September 30, 2021 / CNW / – Purolite, a global manufacturer of resin chromatography separation, purification and extraction technologies, today announced the commercialization of two new next-generation chromatography resins:
1. Praesto® Jetted A50 HipH, is the world’s first protein A stable alkaline resin based on a uniform 50m agarose bead, designed to process the purification of pH sensitive antibodies or other proteins containing Fc. With 40 years of resin bead expertise, Purolite has combined “Jetting” technology – an innovative process that produces uniformly sized agarose beads with a very narrow particle size distribution – with a new protein A ligand, NGL- Impact A Hi pH, from Repligen Society.
2. Praesto® Jetted (dT) 18-DVB is a novel 50 µm styrene jet resin designed to purify mRNA constructs used in vaccine and gene therapy applications. Customer results demonstrate that this new resin outperforms both other dT resin-based solutions and monolith-based dT technology as well.
Chris Major, Managing Director of Purolite said, “We are thrilled with the launch of these two new affinity resins and I am proud that we have transformed the future of affinity chromatography by meeting two key industry requirements. It’s great to work with Repligen again and develop the world’s first protein A resin that offers smoother elution conditions, in the pH region of 5, while delivering a high capacity close to 60g / l. The results show an increase in yield of up to 70% over conventional protein A resins, since aggregation is minimized. Studies have also shown improved protein clearance from the host cell, reducing the burden of future downstream steps. He continued, “The launch of our dT resin was a strategic decision of the company to expand our offering and our knowledge of resins in the rapidly evolving field of critical mRNA therapies in vaccines and applications of. genetical therapy.
Purolite Healthcare & Life Sciences brings innovative thinking and distinguished history of Purolite resin technology expertise to the global life sciences market. In three decades, Purolite has grown into the world’s leading manufacturer of resin technologies and a leader in innovation, with cutting-edge production plants and research laboratories around the world.
Purolite Healthcare & Life Sciences provides APIs, enzyme vectors and immobilized enzymes, as well as resins for purification and separation to support research and development, as well as large-scale applications in pharmaceuticals, protein purification, food production, bioprocessing, fine chemicals and other markets. With a team of world-class researchers and scientists, we develop innovative, high-demand and customized products to meet customer needs..
View original content to download multimedia:https://www.prnewswire.com/news-releases/purolite-announces-the-commercialization-of-two-novel-affinity-chromatography-resins-designed-to-address-the-diversity-in-todays-biomolecule- vaccine-antibody-and-gene-therapy-pipelines-301389025.html